Klygefa (gefurulimab)

Where it stands

Klygefa (gefurulimab), from Alexion Europe, received a positive CHMP opinion on 17 September 2026. The proposed indication is the treatment of adult patients with generalised myasthenia gravis (gMG). The records show no approval date, so the product is not yet authorised in the EU.

A positive CHMP opinion is a recommendation to the European Commission. It is not a marketing authorisation. The authorisation takes legal effect only when the Commission adopts its decision.

The records list an expected EC decision date of 23 November 2026. This is an estimate, not an official date. It is calculated as the opinion date plus 67 days, the standard Commission decision period. The actual timing could differ.

Regulatory pathway and designations

The records place this product in the EU, with a CHMP opinion followed by an EC decision. That is consistent with the centralised procedure. The records do not state the procedure type or any assessment timetable details, such as accelerated assessment.

No designations are recorded for this product. The records do not show orphan status, PRIME or any other special regulatory status. Nothing in the records suggests a conditional or exceptional-circumstances pathway, but they do not rule one out either.

After a CHMP opinion, the Commission normally issues its decision within the standard period. Only the Commission decision confers the right to market in the EU.

Safety and pharmacovigilance

The records contain no safety data, risk management plan details, warnings, contraindications or post-authorisation commitments for Klygefa, so no safety assessment can be made here.

What to watch

The main milestone is the EC decision, estimated for 23 November 2026. Treat that date as indicative until the Commission publishes its decision.

Once the opinion is published, the product information (SmPC) and the assessment report would show the approved indication wording, any safety conditions and any post-authorisation obligations. These are not in the records provided.

Readers should also watch for any change in status from Opinion to Approved. National launch timing, pricing and reimbursement are not covered by the records and cannot be inferred from them.